These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37735924)

  • 1. Physiologically based mechanistic insight into differential risk of valproate hepatotoxicity between children and adults: A focus on ontogeny impact.
    Huang YT; Huang YM; Kung FL; Lin CJ; Jao T; Ho YF
    CPT Pharmacometrics Syst Pharmacol; 2023 Dec; 12(12):1960-1971. PubMed ID: 37735924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations of CYP2C9 and CYP2A6 Polymorphisms with the Concentrations of Valproate and its Hepatotoxin Metabolites and Valproate-Induced Hepatotoxicity.
    Zhao M; Zhang T; Li G; Qiu F; Sun Y; Zhao L
    Basic Clin Pharmacol Toxicol; 2017 Aug; 121(2):138-143. PubMed ID: 28273397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Children versus adults: pharmacokinetic and adverse-effect differences.
    Anderson GD
    Epilepsia; 2002; 43 Suppl 3():53-9. PubMed ID: 12060006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Valproic Acid and Its Main Metabolites' Plasma Concentrations with Clinical Outcomes among Epilepsy Patients: A 10-Year Retrospective Study Based on Therapeutic Drug Monitoring.
    Li RT; Chen ZY; Tang SY; Wen DS; Ren RN; Zhang XX; Liu SZ; Zhou S; Wang XD; Zhou LM; Huang M
    Drug Metab Dispos; 2024 Feb; 52(3):210-217. PubMed ID: 38195521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of CYP2C9 polymorphism on metabolism of valproate and its hepatotoxin metabolite in Iranian patients.
    Amini-Shirazi N; Ghahremani MH; Ahmadkhaniha R; Mandegary A; Dadgar A; Abdollahi M; Shadnia S; Pakdaman H; Kebriaeezadeh A
    Toxicol Mech Methods; 2010 Oct; 20(8):452-7. PubMed ID: 20602621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of CYP2C9-status guided valproic acid therapy in children.
    Bűdi T; Tóth K; Nagy A; Szever Z; Kiss Á; Temesvári M; Háfra E; Garami M; Tapodi A; Monostory K
    Epilepsia; 2015 Jun; 56(6):849-55. PubMed ID: 25967074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of CYP2C9, CYP2A6, ACSM2A, and CPT1A gene polymorphisms with adverse effects of valproic acid in Chinese patients with epilepsy.
    Wang C; Wang P; Yang LP; Pan J; Yang X; Ma HY
    Epilepsy Res; 2017 May; 132():64-69. PubMed ID: 28315807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid.
    Levy RH; Rettenmeier AW; Anderson GD; Wilensky AJ; Friel PN; Baillie TA; Acheampong A; Tor J; Guyot M; Loiseau P
    Clin Pharmacol Ther; 1990 Sep; 48(3):225-35. PubMed ID: 2119269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of valproate dose on formation of hepatotoxic metabolites.
    Anderson GD; Acheampong AA; Wilensky AJ; Levy RH
    Epilepsia; 1992; 33(4):736-42. PubMed ID: 1628592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for valproic acid and divalproex.
    Conner TM; Nikolian VC; Georgoff PE; Pai MP; Alam HB; Sun D; Reed RC; Zhang T
    Eur J Pharm Sci; 2018 Jan; 111():465-481. PubMed ID: 29030176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Hepatic CYP3A4 Ontogeny Functions on Drug-Drug Interaction Risk in Pediatric Physiologically-Based Pharmacokinetic/Pharmacodynamic Modeling: Critical Literature Review and Ivabradine Case Study.
    Lang J; Vincent L; Chenel M; Ogungbenro K; Galetin A
    Clin Pharmacol Ther; 2021 Jun; 109(6):1618-1630. PubMed ID: 33283268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk Factors for Valproic Acid-induced Hyperammonaemia in Chinese Paediatric Patients with Epilepsy.
    Zhu X; Li X; Zhang T; Zhao L
    Basic Clin Pharmacol Toxicol; 2018 Nov; 123(5):628-634. PubMed ID: 29791065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valproate (VPA) metabolites in various clinical conditions of probable VPA-associated hepatotoxicity.
    Siemes H; Nau H; Schultze K; Wittfoht W; Drews E; Penzien J; Seidel U
    Epilepsia; 1993; 34(2):332-46. PubMed ID: 8453944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid-a large-scale study based on naturalistic therapeutic drug monitoring data.
    Smith RL; Haslemo T; Refsum H; Molden E
    Eur J Clin Pharmacol; 2016 Sep; 72(9):1099-104. PubMed ID: 27353638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Age and Genotype on Serum Concentrations of Valproic Acid and Its Hepatotoxic Metabolites in Chinese Pediatric Patients With Epilepsy.
    Zhao M; Chen Y; Wang M; Li G; Zhao L
    Ther Drug Monit; 2020 Oct; 42(5):760-765. PubMed ID: 32107351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid.
    Sadeque AJ; Fisher MB; Korzekwa KR; Gonzalez FJ; Rettie AE
    J Pharmacol Exp Ther; 1997 Nov; 283(2):698-703. PubMed ID: 9353388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous determination of valproic acid and 2-propyl-4-pentenoic acid for the prediction of clinical adverse effects in Chinese patients with epilepsy.
    Chen ZJ; Wang XD; Wang HS; Chen SD; Zhou LM; Li JL; Shu WY; Zhou JQ; Fang ZY; Zhang Y; Huang M
    Seizure; 2012 Mar; 21(2):110-7. PubMed ID: 22055352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship between glucuronide conjugate levels and hepatotoxicity after oral administration of valproic acid.
    Lee MS; Lee YJ; Kim BJ; Shin KJ; Chung BC; Baek DJ; Jung BH
    Arch Pharm Res; 2009 Jul; 32(7):1029-35. PubMed ID: 19641884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative investigation of 2-propyl-4-pentenoic acid (4-ene VPA) and its alpha-fluorinated analogue: phase II metabolism and pharmacokinetics.
    Tang W; Abbott FS
    Drug Metab Dispos; 1997 Feb; 25(2):219-27. PubMed ID: 9029053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of uridine diphosphate glucuronosyltransferase 2B7 -161C>T polymorphism on the concentration of valproic acid in pediatric epilepsy patients.
    Inoue K; Suzuki E; Yazawa R; Yamamoto Y; Takahashi T; Takahashi Y; Imai K; Koyama S; Inoue Y; Tsuji D; Hayashi H; Itoh K
    Ther Drug Monit; 2014 Jun; 36(3):406-9. PubMed ID: 24365988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.